How are CGEM straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the CGEM straddle priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 93.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$474.88 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a CGEM straddle?

The breakeven for the CGEM straddle priced on this page is roughly $5.20 and $14.80 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CGEM market-implied 1-standard-deviation expected move in the same options snapshot is approximately 26.92%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current CGEM implied volatility affect this straddle?

CGEM ATM IV is at 93.90% with IV rank near 17.54%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

CGEM Straddle Strategy

CGEM (Cullinan Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM (Cullinan Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $667.4M, a beta of -0.01 versus the broader market, a 52-week range of 7.93-23.19, average daily share volume of 857K, a public-listing history dating back to 2021, approximately 109 full-time employees. These structural characteristics shape how CGEM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.01 indicates CGEM has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on CGEM?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

CGEM snapshot

As of November 13, 2026, spot at $10.20, ATM IV 93.90%, IV rank 17.54%, expected move 26.92%. The straddle on CGEM below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this straddle structure on CGEM specifically: CGEM IV at 93.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a CGEM straddle, with a market-implied 1-standard-deviation move of approximately 26.92% (roughly $2.75 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CGEM expiries trade a higher absolute premium for lower per-day decay. Position sizing on CGEM should anchor to the underlying notional of $10.20 per share and to the trader's directional view on CGEM stock.

CGEM straddle setup

The CGEM straddle below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CGEM at $10.20 on that close, the first option leg uses a $10.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CGEM chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CGEM shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$10.00	$3.10
Buy 1	Put	$10.00	$1.70

CGEM straddle risk and reward

Net Premium / Debit: -$480.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$474.88
Breakeven(s): $5.20, $14.80
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

CGEM straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on CGEM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$519.00
$2.26	-77.8%	+$293.58
$4.52	-55.7%	+$68.17
$6.77	-33.6%	-$157.25
$9.03	-11.5%	-$382.67
$11.28	+10.6%	-$351.91
$13.54	+32.7%	-$126.50
$15.79	+54.8%	+$98.92
$18.04	+76.9%	+$324.34
$20.30	+99.0%	+$549.75

When traders use straddle on CGEM

Straddles on CGEM are pure-volatility plays that profit from large moves in either direction; traders typically buy CGEM straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

CGEM thesis for this straddle

The market-implied 1-standard-deviation range for CGEM extends from approximately $7.45 on the downside to $12.95 on the upside. A CGEM long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current CGEM IV rank near 17.54% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CGEM at 93.90%. As a Healthcare name, CGEM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CGEM-specific events.

CGEM straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CGEM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CGEM alongside the broader basket even when CGEM-specific fundamentals are unchanged. Always rebuild the position from current CGEM chain quotes before placing a trade.

Frequently asked questions

What is a straddle on CGEM?: A straddle on CGEM is the straddle strategy applied to CGEM (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With CGEM stock at $10.20 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed CGEM chain strike and the premiums come straight from that session's bid/ask midpoint.
How are CGEM straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the CGEM straddle priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 93.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$474.88 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CGEM straddle?: The breakeven for the CGEM straddle priced on this page is roughly $5.20 and $14.80 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CGEM market-implied 1-standard-deviation expected move in the same options snapshot is approximately 26.92%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on CGEM?: Straddles on CGEM are pure-volatility plays that profit from large moves in either direction; traders typically buy CGEM straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current CGEM implied volatility affect this straddle?: CGEM ATM IV is at 93.90% with IV rank near 17.54%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.